HTG2014-Section-Header-publications

Categories

Filter by Topics

1L therapy; bispecific antibodies 478P TA-ness AACR2023 ABC- type ADCC Gene Alteration adolescents AI alcohol consumption ALK alzheimer's Angiogenesis angiosarcoma Anti-TNF Alpha Therapy antibody drug conjugates antiEGFR aplastic anemia AA apoptosis Apoptosis appendiceal neoplasms Asthma Autocrine Signaling Autoimmune Disorder Avelumab B Cells B-accute lyphoblastic leukemia B-ALL B-accute lyphoblastic seukemia B-ALL B-cell lymphoma bacterial vaginosis BCL2A1 BCL6 benign bile acids Biofluid Biology of neoplasia biomarker Biomarker Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers biomarkers Bladder Bladder cancer Bladder Cancer Blastic plasmacytoid dandritic cell neoplasm BPDCN blastoid morphology blindness Blood bone Brain Breast Cancer breast cancer Breast milk Breast Milk Burkitt lymphoma cancer genetics Cancer Genomics cancer therapy CAR T cell therapy CAR-T-cells Cardiovascular Disease Castleman Disease CD10 CD3 CD8 CDK CDK46 inhibitors CDKN1A CDKN2A mutation Cell Free Plasma Cells Cerebrospinal Fluid cervix Cetuximab Chemokines chemotherapy Childhood Atopic Dermatitis children chronic kidney disease Chronic Obstructive Pulmonary Disease Circulating miRNAs circulating tumor Circulating tumor cells classifications Clinical Trial clinical trial cMET cognition cold tumor Colon Colon cancer Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy cornea COVID-19 cultivated limbal epithelial cells Clec Custom mRNA custom panel CXCL12 cyclic AMP‑dependent transcription factor ATF‑4 Cytokine Cytokines Cytotoxic T Cells cytotoxicity dementia Dementia Developmental Immunotherapy Developmental Therapeutics Diabetes diabetic nephropathy Differential Expression Differential Gene Expression Analysis Diffuse Large B-Cell Lymphoma diffuse large B-cell lymphoma DLBCL DLBCL COO DNA damage‑inducible transcript 3 protein DNA lymphoma Drug Response Drug Safety Drug sensitivity Drug Targets Drug-induced Liver Injury dysbiosis Dysplasia ear Efficacy EGFR Muatations EHE cancer EMT Encephalophy end stage kidney disease Endothelial cell EPCORE NHL-1 epidemiology epidermal growth factor receptor EGFRHER Epigenetics epigenomics Epithelial–mesenchymal plasticity Epstein-Barr ERBB3 Esophageal Cancer estrogen and progesteron receptors estrogen receptor 1 ESR1 exosome Exosomes extracellular miRNAs Extracellular Vesicles Extracellular Vesicles Evs extraction-free RNA workflow Fabry Disease farnesoid X receptorcholesterol Feasibility female reproductive tract FFPE FGF Ligand Trap FGFR fibroblast growth factor receptor 4 Fibrous Tumors FOLFOX7 Follicular lymphoma gastrointestinal cancer GEIS Gene Expression gene expression Gene expression analysis gene expression profiling Gene Expression Profiling gene expression signature Gene Fusions Gene Signature Analysis Genetic Polymorphism Genitourinary cancer Glioblastoma Tumors glucocorticoid receptor NR3C1 HARMONIA clinical trial HCC Head and neck cancer Head and Neck Cancer Heart hematologic or solid tumors hepatocellular carcinoma HER HER-2 HER2 HER2- Heterogeneity Histone Deacetylase Inhibitors histone methyltransferase HLA-E Homing hot tumor HPV HR+ HTG EdgeSeq HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL Cell of Origin Assay EU HTG EdgeSeq DLBCL Cell of Origin Panel HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq EGFR KRAS and BRAF Mutation Assay HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq Immuno-Oncology Panel HTG EdgeSeq Lung Fusion Assay HTG EdgeSeq Lymphoma Panel HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq miRNA WTA HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq PATH Assay HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay HTP ibrutinib Ibrutinib Immune Cells Immune Checkpoint Inhibitors Immune microenvironment Immune Related Genes Immune Response Immune System Immune Tolerance Immune-related Colitis Immuno-Oncology immuno-oncology agents immunohistochemistry IHC Immunologically hot tumours IMMUNOSARC immunoscore immunotherapy Immunotherapy Inflammation inhibitor Insulin Resistance Integrins Intrinsic subtypes inverted papilloma IOA- 244 IOA-244 IRF4 IRP IRS-1 ISG JAVELINE bladder Juvenile Arthritis Kidney kikuchi-fujimoto disease KRAS Kruppel-like factor 5 Lactobacillus crispatus LAG3+ Limb ischemia limbal stem cell deficiency LSCD Liposarcoma Liquid Biopsy liver Liver liver disease liver steatosis liver tissue Lung Lung cancer lungs Lupus Lymph Node Metastasis lymphatic Lymphocytes Lymphoid Neoplasia Lymphoma lymphoma lymphomas Machine Learning machine learning malignancy sinonasal malignant mCRC Mechanism of Action Melanoma melanoma Mesothelioma MET metastatic breast cancer MBC metastatic colorectal cancer CRC Method Comparison MIBC Microenvironment microRNA MicroRNA miR-122-5p miR-3937 miRNA miRNA WTA miRNA-375 Molecular Characterization molecular subtypes Mouse Mouse mRNA mouse mRNA TRP mRNA mRNA custom mTOR pathway mTOR signaling multi-omics multiple myeloma Multiple Myeloma MUM1 Muscle Muscle-invasive bladder cancer mutation analysis Mutations MYC NAFLD Nash and Fibrosis native African men Natural Killer Cells Nature Neoantigens Nestin+ Neuroendocrine Tumor Neurologic nivolumab NKG2A Non-alcoholic fatty liver disease non-Hodgink Lymphoma non-Hodgkin Lymphoma Non-Hodgkin lymphoma NHL Non-small cell lung cancer Novel Therapeutic Targets NTRK1 nuclease protection assay Obesity obesity OBP Oesophageal Adenocarcinoma Oncology Oncology-Biomarker OPSCC Optical imaging Oral cancer Oral Cancer Oral cavity Oral lesion Oral Squamous Cell Carcinoma oral squamous cell carcinoma Oropharyngeal Cancer OSCC Osteoarthritis Osteoclast Ovarian cancer palbociclib PALLET PALOMA PALOMA-2 PAM50 Predictive biomarkers Pan-Cancer PanB Pancreas Pancreatic Cancer pancreatic ductal adenocarcinoma PDAC Paralysis Parkinson's Disease Partial EMT Pathogenesis pathophysiology Pathway Analysis Pathway analysis Patient Stratification PAXgene PBMCs PCA Cell Lines PD-1 PD-L1 PDX model PEARL PENELOPE-B PFAS PFNA PFOS Phase III PHOENIX trial PI3K PI3K inhibitors PIK3CA mutation PIP placenta Placenta Plasma Plasma miRNAs Platform Comparison PMAIP1 population based Precision medicine Precision oncology predictive biology Predictive Biomarkers Predictive Modeling Prevotella bivia Programmed cell death protein 1 Progression free-survival progression of renal failure Prostate Prostate Cancer prostate cancer prostate genomics Protein Protein Interaction network qNPA qPCR R-CHOP race disparities Radioimmunotherapy RAS Rbsig Rearrangements Refractory DLBCL Relapsed DLBCL Renal Cell Carcinoma renal cell carcinoma Renal Disease Reproductive Response rate RET Reveal Rhabdomyosarcoma RMS Rheumatoid Arthritis Risk Score ROS1 safety sarcoma Sarcoma SARS-CoV-2 scoring system Sequencing Serum Signaling Inhibitors Signaling Pathways Signature Validation Signatures single cell Single-cell RNA Sinonasal Carcinoma Skin soft tissue sarcoma SPECS Lung Consortium Squamous cell carcinoma squamous cell carcinoma STAT6 pathway STD Sub-typing surface plasmon Surveillance Survival Outcomes Survival plots Synovial Fluid Synovial Sarcoma synthetic miRNA T cells T-Cell T-cells targeted therapeutics Technology Comparison Testicular cancer Therapeutic Response Therapeutic targets Thymic Carcinoma Thyroid Cancer Tislelizumab tislelizumab TMB TME tomentosin Toxicity TP53 mutation transcriptome Transcriptome transcriptome profile transcriptome profiling Translational Medicine Transplantation Treatment Outcome Treatment Stratification Treatment Targets Trichomonas vaginalis Triple Negative Breast CancerTNBC Tumor Biology Tumor Heterogeneity Tumor Immunobiology Tumor infiltrating lymphocytes tumor microenvironment Tumor Microenvironment Urine Urothelial carcinoma Uterus vagina VEGFR vestibular schwannoma VS virus Waldeyer's ring Wound healing Xenograft Tissue Zanubrutinib Zanubrutinlb ZEB1

2020

77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

Hou, M. M., et al. 77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC). Journal for Immunotherapy of Cancer 2020(8)S3. Pre-print

Download pdf 946KB

78 T-Cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma

Ye, D., et al. 78 T-Cell, MHC I, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. Journal for Immunotherapy of Cancer 2020(8)S3: A1-A959- pre-print

Download pdf 1.0MB

A Pilot Study Comparing the efficacy of Lactate Dehydrogenase Levels Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients

Bustos, M. A., et al. A Pilot Study Comparing the efficacy of Lactate Dehydrogenase Levels Circulating Cell-Free microRNAs in Monitoring Responses to Checkpoint Inhibitor Immunotherapy in Metastatic Melanoma Patients. Cancers 2020, 12, 3361; doi:10.3390/cancers12113361

Download pdf 2.0MB

A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients

Wang, Z., et al. A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients. Lung Cancer 147(2020) 259-268. 

Download pdf 4.3MB

Comparative Transcriptomics of Prostate Tumor Show Enrichment of Biologically Distinct Pathways Among Men of African Origin

Yamoah, K., et al. Comparative Transcriptomics of Prostate Tumor Show Enrichment of Biologically Distinct Pathways Among Men of African Origin. International Journal of Radiation Oncology, Biology, Physics. Oral Scientific Session 2020 NOV 1 (108)3;S48

Download pdf 188KB

Development and Verification of the HTG EdgeSeq Reveal Immune, Stroma and TME Signatures

Development and Verification of the HTG EdgeSeq™ Reveal Immune, Stroma and TME Signatures

Download pdf 870KB

Proof-of-Concept for a Whole Transcriptome Panel Using HTG EdgeSeq™ Technology

Proof-of-Concept for a Whole Transcriptome Panel Using HTG EdgeSeq™ Technology

Download pdf 192KB

Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues.

Kwak, M., et al. Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues.Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues. Scientific Reports (2020) 10:18336. https://doi.org/10.1038/s41598-020-74996-9 Nature Research

Download pdf 1.3MB

Page last updated May 22, 2023